Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
Press releases published on May 9, 2025
SRx Health Solutions Announces Intention to Create Subsidiary for Crypto-Based Borrowing
GlobeNewswire
·
May 9, 2025
TAMPA, Fla., May 09, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced its intention to create a subsidiary to borrow Solana, Bitcoin, and other …
Cytel Partners with Nested Knowledge to Power the Next Generation of AI-Enhanced LiveSLR® for HEOR and HTA
GlobeNewswire
·
May 9, 2025
Cambridge, MA and St. Paul, MN, May 09, 2025 (GLOBE NEWSWIRE) -- Cytel, a global leader in evidence generation and data-driven decision-making, today announced a partnership with Nested Knowledge, a pioneer in AI-powered systematic literature review …
Vystar Develops Revolutionary Leap in Air Purification Utilizing its Patented Hughes Reactor
GlobeNewswire
·
May 9, 2025
Boston, MA, May 09, 2025 (GLOBE NEWSWIRE) -- Vystar® Corporation (OTCQB: VYST) Vystar has completed what it believes to be a revolutionary, next-generation RXAIR prototype using the new Fluid Energy Conversion - Hughes Reactor. The Hughes Reactor was …
Celularity Announces Full Year 2024 Operating and Financial Results
GlobeNewswire
·
May 9, 2025
FLORHAM PARK, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity” or the “Company”), a regenerative and cellular medicine company, today announced operating and financial results for the year ended December 31, 2024. “We …
LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia
GlobeNewswire
·
May 9, 2025
SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. (“Lotus”, TWSW Stock Code: 1795) today announced an exclusive license and commercialization agreement for Lotus to …
SAB BIO Announces Q1 2025 Financial Results and Provides Company Updates
GlobeNewswire
·
May 9, 2025
MIAMI, May 09, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS), (“SAB BIO” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the …
Outset Medical to Present at RBC Global Healthcare Conference
GlobeNewswire
·
May 9, 2025
SAN JOSE, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of …
NEXGEL to Report First Quarter 2025 Financial Results on May 13th
GlobeNewswire
·
May 9, 2025
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., May 09, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for …
SRx Health Solutions Purchases $1.5 Million of Solana Tokens as Part of its Asset Allocation Diversification Strategy
GlobeNewswire
·
May 9, 2025
TAMPA, Fla., May 09, 2025 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the “Company”), a leading global health and wellness company, today announced purchasing Solana Tokens (SOL) for approximately $1.5 million as part of the …
Best Bodybuilding Supplements: Top Legal Steroids & Supplements For Bodybuilding & Muscle Growth
GlobeNewswire
·
May 9, 2025
Glasgow, May 09, 2025 (GLOBE NEWSWIRE) -- Introduction: Best Bodybuilding Supplements to Accelerate Muscle Growth—Including Legal Steroids In the competitive world of fitness and bodybuilding, every rep, every gram of protein, and every supplement you take …
Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases
GlobeNewswire
·
May 9, 2025
Conduit secures a composition of matter patent from the Korean Intellectual Property Office for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune disorders, positioning the Company for clinical development and strategic partnerships. …
Ocugen Provides Business Update with First Quarter 2025 Financial Results
GlobeNewswire
·
May 9, 2025
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 3 clinical trial for retinitis pigmentosa (RP) is progressing well and on target for potential BLA/MAA filings by mid-2026 Anticipate initiating OCU410ST Phase 2/3 pivotal confirmatory clinical …
Alvotech Meets Investors and Participates in Fireside Chat At the BofA Securities Healthcare Conference 2025 in Las Vegas, Nevada
GlobeNewswire
·
May 9, 2025
REYKJAVIK, Iceland, May 09, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the BofA Securities …
Garuda Therapeutics Announces Name Change to Stratus Therapeutics to Reflect Mission of Pioneering Full Hematopoietic System Renewal
GlobeNewswire
·
May 9, 2025
CAMBRIDGE, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Garuda Therapeutics (“Garuda”), a biotechnology company developing off-the-shelf hematopoietic stem cell (HSC) therapies, today announced that it has changed its name to Stratus Therapeutics, Inc. (“ …
Humacyte to Present First Quarter Financial Results and Provide Corporate Update on May 13, 2025
GlobeNewswire
·
May 9, 2025
DURHAM, N.C., May 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, will release its financial results for the …
PMV Pharmaceuticals Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
May 9, 2025
Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumors Interim analysis from Phase 2 PYNNACLE trial expected mid-2025; PMV plans to …
BlossomHill Therapeutics Appoints Jason Keyes as Chief Financial Officer and Executive Vice President
GlobeNewswire
·
May 9, 2025
SAN DIEGO, May 09, 2025 (GLOBE NEWSWIRE) -- BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biotechnology company focused on the design and development of small molecule medicines for treating cancer and autoimmune diseases, today …
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
GlobeNewswire
·
May 9, 2025
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy …
Cognition Therapeutics Presented Data at Association for Research in Vision and Ophthalmology Showing Impact on Retinal Cell Health
GlobeNewswire
·
May 9, 2025
PURCHASE, N.Y., May 09, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported preclinical data this week at the Association for Research in Vision …
Spectral Medical Announces First Quarter and Provides Corporate Update
GlobeNewswire
·
May 9, 2025
Tigris Trial Enrollment completed Topline results expected to be released in August 2025 Entered into an up to US$10 million Promissory Note with Vantive to Fund Spectral to PMX commercialization TORONTO, May 09, 2025 (GLOBE NEWSWIRE) -- Spectral Medical …